Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician's choice chemotherapy treatment (PCT): A focus on the EMBRACA triple negative (TNBC) subpopulation

被引：0

作者：

Rugo, H. S. ^{[1
]}

Quek, R. ^{[2
]}

Ettl, J. ^{[3
]}

Hurvitz, S. A. ^{[4
]}

Bhattacharyya, H. ^{[2
]}

Hannah, A. L. ^{[5
]}

Litton, J. K. ^{[6
]}

机构：

[1] UCSF Helen Diller Family Comprehens Canc Ctr, Breast Canc Ctr, San Francisco, CA USA

[2] Pfizer Inc, Hlth Econ, San Francisco, CA USA

[3] Tech Univ Munich, Obs Gyn, Munich, Germany

[4] Univ Calif Los Angeles, Hematol Oncol, Santa Monica, CA USA

[5] Pfizer Inc, Oncol, San Francisco, CA USA

[6] Univ Texas MD Anderson Canc Ctr, Breast Med Oncol, Houston, TX 77030 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

292O

引用

页数：1